PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
9.86%
ROE 5-10% – Below desirable range. Philip Fisher would scrutinize management efficiency. Verify future expansion plans.
-447.55%
Negative ROA indicates net losses or excessive assets. Benjamin Graham would question viability or capital misallocation.
28.09%
ROCE above 25% – Excellent capital efficiency. Warren Buffett would verify if this stems from a sustainable competitive advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.